AEG33773

AEG33773 is an orally bioavailable small molecule developed by Aegera Therapeutics for the treatment of painful diabetic neuropathy and potentially other chronic pain conditions. Its mechanism of action involves stimulation of heat shock protein 90 (HSP90), which is believed to contribute to its analgesic effects. Preclinical studies demonstrated efficacy in models of neuropathic and inflammatory pain, showing both prevention and reversal of established neuropathies. Clinical development included Phase 1 trials assessing safety and tolerability, followed by a Phase 2 proof-of-concept study evaluating its efficacy in reducing pain associated with chronic diabetic peripheral neuropathy[1][4][5].